Related references
Note: Only part of the references are listed.Pharmacokinetic Optimization of Antiretroviral Therapy in Children and Adolescents
Michael N. Neely et al.
CLINICAL PHARMACOKINETICS (2011)
Emerging antiretroviral drug interactions
Paul A. Pham et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children
Amanda H. Corbett et al.
ANTIVIRAL THERAPY (2010)
Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial
Victor Musiime et al.
ANTIVIRAL THERAPY (2010)
Treating an HIV-infected paediatric patient: an easy task?
Natella Y. Rakhmanin et al.
ANTIVIRAL THERAPY (2010)
Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-< 36 months
Evelyne Jacqz-Aigrain et al.
ANTIVIRAL THERAPY (2010)
The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children
Brenda Waning et al.
BMC PEDIATRICS (2010)
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action
Caroline Bazzoli et al.
CLINICAL PHARMACOKINETICS (2010)
The Clinical Care of the HIV-1-Infected Infant
Andres F. Camacho-Gonzalez et al.
CLINICS IN PERINATOLOGY (2010)
A Highly Concentrated and Taste-Improved Aqueous Formulation of Efavirenz for a More Appropriate Pediatric Management of the Anti-HIV Therapy
Diego A. Chiappetta et al.
CURRENT HIV RESEARCH (2010)
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all
Awewura Kwara et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Efavirenz in the therapy of HIV infection
Natella Y. Rakhmanina et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Pharmacokinetic evaluation of etravirine
Laura Dickinson et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Pediatric antiretroviral therapy
Adriana Cedilla et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2010)
Use of Generic Antiretroviral Agents and Cost Savings in PEPFAR Treatment Programs
Charles B. Holmes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Oral medication administration: Implications caused by capsule splitting
Sarah Mae Caldwell et al.
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2010)
THERAPEUTIC DRUG MONITORING OF LOPINAVIR IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN RECEIVING ADULT TABLETS
Thanyawee Puthanakit et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2010)
Can Therapeutic Drug Monitoring Improve Pharmacotherapy of HIV Infection in Adolescents?
Natella Y. Rakhmanina et al.
THERAPEUTIC DRUG MONITORING (2010)
CYP2B6 Polymorphism and Nonnucleoside Reverse Transcriptase Inhibitor Plasma Concentrations in Chinese HIV-Infected Patients
Jun Chen et al.
THERAPEUTIC DRUG MONITORING (2010)
Experiencing antiretroviral adherence: helping healthcare staff better understand adherence to paediatric antiretrovirals
Benjamin R. Phelps et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2010)
Is the Recommended Dose of Efavirenz Optimal in Young West African Human Immunodeficiency Virus-Infected Children?
Deborah Hirt et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Population Pharmacokinetics of Lopinavir Predict Suboptimal Therapeutic Concentrations in Treatment-Experienced Human Immunodeficiency Virus-Infected Children
Natella Rakhmanina et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Clinical Pharmacokinetics and Pharmacodynamics of Etravirine
Monika Scholler-Gyure et al.
CLINICAL PHARMACOKINETICS (2009)
Management of paediatric HIV-1 resistance
Ravindra K. Gupta et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2009)
PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection
Steven Welch
HIV MEDICINE (2009)
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets
Louisa Pollock et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
STEADY-STATE PHARMACOKINETICS OF LOPINAVIR/RITONAVIR IN COMBINATION WITH EFAVIRENZ IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PEDIATRIC PATIENTS
Jennifer R. King et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2009)
Pharmacologic aspects of new antiretroviral drugs
Mary C. Long et al.
Current HIV/AIDS Reports (2009)
Analysis of weight uniformity, content uniformity and 30-day stability in halves and quarters of routinely prescribed cardiovascular medications
Marco L. Margiocco et al.
Journal of Veterinary Cardiology (2009)
Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets
Rafaella F. A. L'homme et al.
AIDS (2008)
Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors
Brian L. Robbins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Current and future antiretroviral treatment options in paediatric HIV infection
Carlo Giaquinto et al.
CLINICAL DRUG INVESTIGATION (2008)
Long-term effectiveness of highly active Antiretroviral therapy on the survival of children and adolescents with HIV infection:: A 10-year follow-up study
Kunjal Patel et al.
CLINICAL INFECTIOUS DISEASES (2008)
Optimizing Oral Medications for Children
Julie A. Mennella et al.
CLINICAL THERAPEUTICS (2008)
Global challenges in the development and delivery of paediatric antiretrovirals
Asha Bowen et al.
DRUG DISCOVERY TODAY (2008)
Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children
U. Wintergerst et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy
Miguel Goicoechea et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus
Julia B. Purdy et al.
JOURNAL OF PEDIATRICS (2008)
Pediatric drugs - A review of commercially available oral formulations
Robert G. Strickley et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa
Catherine G. Sutcliffe et al.
LANCET INFECTIOUS DISEASES (2008)
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients
J. J. Kiser et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial
C. V. Fletcher et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling
H. Vermeiren et al.
JOURNAL OF VIROLOGICAL METHODS (2007)
Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice
Jose Molto et al.
THERAPEUTIC DRUG MONITORING (2007)
Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS clinical trials group protocol P1021
Ross E. McKinney et al.
PEDIATRICS (2007)
Practical approaches of taste masking technologies in oral solid forms
Dionysios Douroumis
EXPERT OPINION ON DRUG DELIVERY (2007)
High prevalence of subtherapeutic plasma concentrations of efavirenz in children
Yuan Ren et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS
Patricia A. Garvie et al.
PEDIATRICS (2007)
Increasing antiretroviral drug access for children with HIV infection
Jennifer Swan et al.
PEDIATRICS (2007)
Once-daily highly active antiretroviral therapy for HIV-infected children: Safety and efficacy of an efavirenz-containing regimen
Henriette J. Scherpbier et al.
PEDIATRICS (2007)
Efavirenz and nevirapine in HIV-1 infection - Is there a role for clinical pharmacokinetic monitoring?
Karen Dahri et al.
CLINICAL PHARMACOKINETICS (2007)
In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy
Daniel P. O'Brien et al.
AIDS (2006)
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: Impact on bone mineral density in HIV-infected children
Rachel I. Gafni et al.
PEDIATRICS (2006)
Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children
Kristel M. L. Crommentuyn et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2006)
Adherence and acceptability of once daily lamivudine and abacavir in human immunodeficiency virus type-1 infected children
Marthe LePrevost et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2006)
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy
F Van Leth et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2006)
An update on therapeutic drug monitoring for antiretroviral drugs
David Back et al.
THERAPEUTIC DRUG MONITORING (2006)
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection
R Hazra et al.
PEDIATRICS (2005)
Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents - Pediatric AIDS clinical trials group protocol 403
JR King et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2005)
Nevirapine plasma exposure affects both durability of viral suppression and selection of Nevirapine primary resistance mutations in a clinical setting
DG de Requena et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life
A Kovacs et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2005)
Pharmacotherapy of perinatal HIV
E Capparelli et al.
SEMINARS IN FETAL & NEONATAL MEDICINE (2005)
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors
MS Sulkowski
CLINICAL INFECTIOUS DISEASES (2004)
Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children
DM Burger et al.
JOURNAL OF PEDIATRICS (2004)
Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children
R Hazra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis
ML Newell et al.
LANCET (2004)
Changes in indinavir exposure over time: a case study in six HIV-1-infected children
PLA Fraaij et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Adherence issues in children and adolescents receiving highly active antiretroviral therapy
M Goode et al.
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV (2003)
Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children
EV Capparelli et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations
DM Burger et al.
THERAPEUTIC DRUG MONITORING (2003)
Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial
DM Gibb et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2003)
Pharmacokinetics and tolerance of zidovudine in preterm infants
EV Capparelli et al.
JOURNAL OF PEDIATRICS (2003)
Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir
AMC van Rossum et al.
PEDIATRICS (2002)
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection
RB Van Dyke et al.
PEDIATRICS (2002)
Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1
P Krogstad et al.
CLINICAL INFECTIOUS DISEASES (2002)
Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection
S Grub et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Antiretroviral pharmacokinetics in the paediatric population - A review
JR King et al.
CLINICAL PHARMACOKINETICS (2002)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini et al.
AIDS (2001)
Adherence to medication regimens among children with human immunodeficiency virus infection
C Reddington et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2000)
Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients
JL Powers et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2000)
Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons
CV Fletcher et al.
AIDS (2000)
Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus
D Shingadia et al.
PEDIATRICS (2000)
Factors affecting adherence to antiretroviral therapy
MA Chesney
CLINICAL INFECTIOUS DISEASES (2000)
Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children
RC Stevens et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2000)
Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy
CV Fletcher et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children
T Abreu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
